SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13(d)-2(b)
(Amendment No.1)
SYNSORB BIOTECH INC.
------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
------------------------------------------------------------------------
(Title of Class of Securities)
87160V104
------------------------------------------------------------------------
(CUSIP Number)
June 1, 1999
------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ X / Rule 13d-1(c)
/ / Rule 13d-1(d)
<PAGE>
CUSIP No. 87160V104 13G/A
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
The Erin Mills Development Corporation
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF
A GROUP* (a) / /
(b) / /
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Ontario, Canada
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 6 SHARED VOTING POWER 125,000
OWNED BY
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 8 SHARED DISPOSITIVE POWER 125,000
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
125,000
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* / /
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0.429%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 87160V104 13G/A
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
The Erin Mills Investment Corporation
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF
A GROUP* (a) / /
(b) / /
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Ontario, Canada
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 6 SHARED VOTING POWER 125,000
OWNED BY
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 8 SHARED DISPOSITIVE POWER 125,000
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
125,000
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* / /
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0.429%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
STATEMENT ON SCHEDULE 13G
This Amendment No.1 to Schedule 13G (the "Schedule 13G") relates to
the common stock, par value $.01 per share ("Common Stock"), of SYNSORB
Biotech Inc. (the "Company"), and is being filed as an amendment to the
initial statement on Schedule 13G filed with the Securities and Exchange
Commission ("the Commission") on February 17, 1998. This statement is
being filed on behalf of The Erin Mills Development Corporation, an
Ontario, Canada corporation ("EMDC"), as the indirect beneficial owner of
the shares of Common Stock reported as beneficially owned in this
statement, and The Erin Mills Investment Corporation, an Ontario, Canada
corporation and majority owned subsidiary of EMDC ("TEMIC"), as the direct
beneficial owner of the shares of Common Stock reported as beneficially
owned in this statement.
Schedule 13G is hereby amended and supplemented as follows:
ITEM 1(A) NAME OF ISSUER.
SYNSORB Biotech Inc.
ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
Suite 201, 1204 Kensington Road N.W.
Calgary, Alberta, T2N 3P5
CANADA
ITEM 4 OWNERSHIP.
See Items 5 through 11 on page 2 for EMDC and page 3 for
TEMIC.
ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of
more than 5% of the class of securities, check the following [ X ].
EXHIBITS EXHIBIT 1
Joint Filing Agreement dated June 9, 1999 between TEMIC and
EMDC.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: June 14, 1999
THE ERIN MILLS DEVELOPMENT CORPORATION
By: /s/ Gerry Quinn
----------------------------
Gerry Quinn
Executive Vice-President
THE ERIN MILLS INVESTMENT CORPORATION
By: /s/ Gerry Quinn
----------------------------
Gerry Quinn
President
<PAGE>
EXHIBIT INDEX
EXHIBIT DESCRIPTION
- ------- -----------
1 Joint Filing Agreement dated June 9, 1999 between
TEMIC and EMDC.
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act
of 1934, as amended, the undersigned agree to the joint filing on behalf of
each of them of a Statement on Schedule 13G (including any and all
amendments thereto) with respect to the Common Stock, par value $.01 per
share, of SYNSORB Biotech Inc., and further agree that this Joint Filing
Agreement shall be included as an Exhibit to such joint filings.
The undersigned further agree that each party hereto is responsible
for timely filing of such Statement on Schedule 13G and any amendments
thereto, and for the accuracy and completeness of the information
concerning such party contained therein; provided, however, that no party
is responsible for the accuracy or completeness of the information
concerning any other party, unless such party knows or has reason to
believe that such information is inaccurate.
This Joint Filing Agreement may be signed in counterparts with the
same effect as if the signature on each counterpart were upon the same
instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
June 9, 1999.
THE ERIN MILLS DEVELOPMENT CORPORATION
By: /s/ Gerry Quinn
----------------------------
Gerry Quinn
Executive Vice-President
THE ERIN MILLS INVESTMENT CORPORATION
By: /s/ Gerry Quinn
----------------------------
Gerry Quinn
President
